Corona Remedies IPO: A New Opportunity for Indian Investors
Corona Remedies Ltd., a leading pharmaceutical formulation company, has fixed its price band for its upcoming initial public offering (IPO) at Rs 1,008-1,062 per share. The IPO is set to open on Dec. 8, providing Indian investors with a new opportunity to participate in the growth of the country’s pharmaceutical sector.
About Corona Remedies
Headquartered in Ahmedabad, Corona Remedies is engaged in developing, manufacturing, and marketing products in various therapeutic areas, including women’s healthcare, cardio-diabeto, pain management, urology, and others. The company’s diversified product portfolio comprises 67 brands, catering to a range of therapeutic areas as of December 2024.
According to the Crisil Intelligence Report, Corona Remedies is the second fastest-growing firm among the top 30 companies in the Indian pharmaceutical market in terms of domestic sales performance from Moving Annual Total (MAT) June 2022 to June 2025. During this period, the company’s domestic sales grew at a Compound Annual Growth Rate (CAGR) of 16.77% compared to the IPM, which grew at a CAGR of 9.21%.
IPO Details
The Corona Remedies IPO is entirely an Offer For Sale (OFS) by promoters and existing investors, with a revised IPO size of Rs 655.37 crore, lower than the initially planned Rs 800 crore. The price band has been fixed at Rs 1,008-1,062 per share, valuing the company at nearly Rs 6,500 crore.
Half of the issue size has been reserved for qualified institutional buyers, 35% for retail investors, and the remaining 10% for non-institutional investors. JM Financial, IIFL Capital Services, and Kotak Mahindra Capital Company are the book-running lead managers to the issue.
Investment Opportunities
The Corona Remedies IPO provides Indian investors with an opportunity to participate in the growth of the country’s pharmaceutical sector, which has been witnessing significant growth in recent years. With its diversified product portfolio and strong growth trajectory, Corona Remedies is well-positioned to capitalize on the growing demand for pharmaceutical products in India.
However, investors should carefully evaluate the company’s financials, management team, and industry trends before making an investment decision. It is also essential to consider the risks and challenges associated with the pharmaceutical industry, including regulatory changes, competition, and pricing pressure.
Conclusion
The Corona Remedies IPO is a significant event in the Indian stock market, providing investors with an opportunity to participate in the growth of the country’s pharmaceutical sector. With its strong growth trajectory, diversified product portfolio, and experienced management team, Corona Remedies is well-positioned for long-term success.
Investors can stay updated on the latest news and developments related to the Corona Remedies IPO by visiting our website, which provides comprehensive coverage of the Indian stock market and IPO updates. We also offer insights and analysis on the pharmaceutical industry trends and the Indian economy, helping investors make informed decisions.